Based on the analysis of Gossamer Bio's profitability, liquidity, and operating efficiency, Gossamer Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August. At this time, Gossamer Bio's Net Working Capital is comparatively stable compared to the past year. Property Plant And Equipment Net is likely to gain to about 7.5 M in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 145.2 M in 2025. Key indicators impacting Gossamer Bio's financial strength include:
The financial analysis of Gossamer Bio is a critical element in measuring its lifeblood. Investors should not minimize Gossamer Bio's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Understanding current and past Gossamer Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Gossamer Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Gossamer Bio's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Gossamer Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gossamer Bio. Check Gossamer Bio's Beneish M Score to see the likelihood of Gossamer Bio's management manipulating its earnings.
Gossamer Bio Stock Summary
Gossamer Bio competes with Cabaletta Bio, Larimar Therapeutics, Q32 Bio, Day One, and Alector. Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. Gossamer Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 185 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Gossamer Bio's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Gossamer Bio's current stock value. Our valuation model uses many indicators to compare Gossamer Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gossamer Bio competition to find correlations between indicators driving Gossamer Bio's intrinsic value. More Info.
Gossamer Bio is rated below average in return on equity category among its peers. It is rated # 2 in return on asset category among its peers . At this time, Gossamer Bio's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Gossamer Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Gossamer Bio Systematic Risk
Gossamer Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Gossamer Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Gossamer Bio correlated with the market. If Beta is less than 0 Gossamer Bio generally moves in the opposite direction as compared to the market. If Gossamer Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Gossamer Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Gossamer Bio is generally in the same direction as the market. If Beta > 1 Gossamer Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Gossamer Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Gossamer Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Gossamer Bio growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Gossamer Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Gossamer Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Gossamer Bio based on widely used predictive technical indicators. In general, we focus on analyzing Gossamer Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Gossamer Bio's daily price indicators and compare them against related drivers.
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.